Business Context and Reporting Period
NanoViricides, Inc. (NNVC) is a clinical-stage biopharmaceutical company developing broad-spectrum antiviral drugs using a proprietary "nanoviricide" platform. The company focuses on host-mimetic nanomedicines designed to dismantle viruses without relying on the patient's immune system. This Form 10-K covers the fiscal year ended June 30, 2025.
The company has no commercial products, no customers, and no revenue to date. Its primary asset is its drug pipeline, led by NV-387, a broad-spectrum antiviral candidate that has completed Phase Ia/Ib safety trials in healthy subjects with no reported adverse events. The company owns its own cGMP-capable manufacturing facility in Shelton, Connecticut.
Key Financial Metrics
| Metric | Fiscal Year 2025 | Fiscal Year 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(9,467,000) | $(8,294,000) |
| Research & Development Expenses | $5,549,000 | $5,437,000 |
| General & Administrative Expenses | $4,043,000 | $3,079,000 |
| Cash and Cash Equivalents (End of Period) | $1,559,000 | $4,798,000 |
| Net Cash Used in Operating Activities | $(8,479,000) | $(6,316,000) |
| Accumulated Deficit | $(148,842,000) | $(139,375,000) |
| Long-Term Assets (Net) | $6,834,000 | $7,512,000 |
Note: The filing text does not provide specific gross margin or operating margin data as the company has no revenue.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by approximately $1.17 million (14%) year-over-year, driven primarily by a $964,000 increase in General and Administrative expenses due to higher professional services and investor outreach costs.
- Cash Burn: Cash and cash equivalents decreased by approximately $3.24 million, reflecting a net cash outflow from operations of $8.48 million, partially offset by $5.30 million in net proceeds from equity financing (ATM sales).
- Financing Activity: The company sold 3,351,096 shares of common stock under its At-The-Market (ATM) program during the fiscal year, raising approximately $5.3 million in net proceeds.
- Related Party Transactions: Development fees charged by related party TheraCour Pharma, Inc. remained relatively stable at approximately $2.49 million for FY2025 compared to $2.55 million in FY2024.
Guidance, Outlook, and Risks
Outlook and Management Commentary
Management is focused on advancing NV-387 into Phase II clinical trials for two primary indications:
- MPox (Monkeypox): A Phase II trial is planned for the Democratic Republic of Congo (DRC). Preliminary ethics approval has been obtained.
- Viral Acute/Severe Acute Respiratory Infections (ARI/SARI): An adaptive "basket-type" Phase II trial is being designed to evaluate efficacy against multiple respiratory viruses (Influenza, RSV, Coronaviruses) simultaneously.
The company also plans to pursue Orphan Drug Designations for MPox, Smallpox, and Measles, and seeks non-dilutive government funding for biodefense applications (Smallpox).
Risks and Contingencies
- Going Concern: The company has raised substantial doubt about its ability to continue as a going concern. With approximately $1.6 million in cash and a $3 million undrawn line of credit, management believes current resources are insufficient to fund operations for the next 12 months without additional financing.
- Capital Requirements: The company must raise substantial additional capital to fund Phase II trials and ongoing operations. There is no assurance that equity or debt financing will be available on acceptable terms.
- Related Party Dependence: The company relies exclusively on TheraCour Pharma, Inc. (controlled by the CEO) for the development and manufacturing of its core drug candidates. Milestone payments to TheraCour are contingent on future revenues.
- Regulatory Uncertainty: As a clinical-stage company with no approved products, there is significant risk that drug candidates will fail to demonstrate efficacy or safety in human trials or fail to obtain regulatory approval.
Key Facts for Investor Verification
- Liquidity Status: Verify the sufficiency of the $1.6 million cash balance and the $3 million line of credit against the estimated $11 million budget required for the next 12-18 months of operations and clinical trials.
- Phase II Trial Initiation: Confirm the timeline and regulatory status of the Phase II MPox trial in the DRC and the Phase II ARI/SARI trial, as these are critical milestones for future funding.
- Related Party Agreements: Review the terms of the license agreements with TheraCour, specifically the milestone payment structures and the requirement for TheraCour to perform all R&D and manufacturing.
- Equity Dilution: Monitor the rate of share issuance under the ATM program and the potential dilution from future financing rounds required to sustain operations.
- Intellectual Property: Verify the status of patent applications (PCT/US21/39050 and PCT/US22/35210) and the exclusivity of the licenses held from TheraCour.